Ascend Capital’s Nektar Therapeutics NKTR Stock Holding History

Ascend Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-6,459	Closed	-$1.19M	–	169
2016 Q4	$1.19M	Buy	+6,459	New	+$1.31M	0.06%	127

Other funds holding NKTR

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ascend Capital's NKTR Position: Q1 2017 in Review

Ascend Capital sold out of Nektar Therapeutics (NKTR) in Q1 2017, closing a stake of 6,459 shares — an estimated $1.19M sold.

Ascend Capital first reported a position in NKTR in Q4 2016 and held it in 1 quarter. The position peaked at $1.19M in Q4 2016. 201 funds tracked by Wall St. Rank hold NKTR as of Q1 2017.

Ascend Capital reported no remaining Nektar Therapeutics position as of Q1 2017 after selling out during the quarter.
Ascend Capital sold 6,459 Nektar Therapeutics shares in Q1 2017, an estimated $1.19M.
Ascend Capital first reported a position in Nektar Therapeutics in Q4 2016 and held it in 1 quarter.
Ascend Capital's Nektar Therapeutics position peaked at $1.19M in Q4 2016.
201 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2017.

Based on Ascend Capital's 13F filing for Q1 2017, filed 15 May 2017.